Literature DB >> 2224203

Hypocalcemia in cancer.

E C Abramson1, H Gajardo, S C Kukreja.   

Abstract

Hypocalcemia based on total calcium measurement is frequent in certain cancers (especially prostate) in association with osteosclerotic bone metastases. In a majority of these patients hypocalcemia is related to the low serum albumin and/or renal failure. True ionized hypocalcemia may be seen as a toxic effect of certain chemotherapeutic agents or as a consequence of hyperphosphatemia due to rapid tumor lysis. In addition, tumors may produce osteoblast-stimulating factor(s) which cause massive accretion of calcium by the skeleton. Isolation and purification of these factors may provide us with unique osteoblast-stimulating factors which may have therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2224203     DOI: 10.1016/0169-6009(90)90259-i

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  3 in total

Review 1.  Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.

Authors:  Prashanth Peddi; Maria A Lopez-Olivo; Gregory F Pratt; Maria E Suarez-Almazor
Journal:  Cancer Treat Rev       Date:  2012-08-13       Impact factor: 12.111

2.  Acute tumour lysis syndrome with no evidence of tumour load.

Authors:  R D Hain; E Harvey; A O Poon; S Weitzman
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

3.  Hypocalcemia: a key biomarker in hospitalized COVID-19 patients.

Authors:  M J Ruiz-Álvarez; Emanuela Stampone; Yaiza Fernández Verduras; Giovanni Gallo; Marta Barrionuevo González; Belén Beteré Cubillo; Debora Bencivenga; Fulvio Della Ragione; Adriana Borriello
Journal:  Biomed J       Date:  2022-08-26       Impact factor: 7.892

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.